Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Summary

This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.

Timeline

Start

2015-01

Primary completion

2017-11-10

Completion

2017-11-10

Outcome

Outcome not reported

Stopped: “Closed after being on administrative hold”

Drugs

Indications